Best Diversified Pharmaceuticals Companies in New Jersey, United States
The 48 best Diversified Pharmaceuticals companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: The Medicines Company.
Ranked: Best Diversified Pharmaceuticals companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | The Medicines Company Markets and developing drugs in areas of acute cardiovascular care, infectious disease care and perioperative… | $400M | 122 mo ago | 60 | — | — | 251 patents Single-dose glycopeptide antibiotics and nanoparticle drug delivery formulations for infections | — |
| 2 | Salix Pharmaceuticals Gastrointestinal specialty pharmaceutical company dedicated to advancing treatment and patient care | $345M | 152 mo ago | 1,000 | — | BootstrapAzureMicrosoft Application Insights+12 | 669 patents Formulating rifaximin solid dispersions for improved GI drug delivery and hepatic encephalopathy treatment. | — |
| 3 | Palatin Technologies Innovating melanocortin therapeutics for inflammatory, autoimmune, and ocular diseases | $78M | 51 mo ago | 34 34 → 50 (+47%) | John Prendergast Co-Founder and Chairman of the Board | WordPressMySQLSalesforce+21 | 377 patents Patents concentrated in health & consumer products | — |
| 4 | NPS Pharma Global pharmaceutical company committed to better health and a brighter future | $50M | 143 mo ago | 365 | — | — | 433 patents GLP‑2 peptide therapeutics and ion‑channel modulators for short bowel syndrome treatment | — |
| 5 | Sapphire Therapeutics Small molecule drugs for metabolic and oncologic disorders | $49M | — | — | Gary Cupit Ex-CEO and President | — | — | — |
| 6 | Celgene Developer of therapies for treating cancer and inflammatory diseases | $45M | 102 mo ago | 4,891 | Jerome Zeldis Chairman & CEO | — | 5,473 patents Design and synthesis of heteroaryl small‑molecule PROTACs targeting IRAK kinases for cancer therapy | — |
| 7 | Citius Pharmaceuticals Developer of drugs for the infectious and gastrointestinal diseases | $43M | 66 mo ago | 22 22 → 19 (-14%) | — | Q4MediaElement.jsMicrosoft ASP.NET+14 | — | — |
| 8 | Pharmos US-based, clinical-stage biopharma developing therapeutics for Neurology, Gastrointestinal… | $41M | 207 mo ago | — | Haim Aviv Founder | — | 48 patents Novel therapeutic small molecules for gout, anti‑inflammatory steroids, sulfonamides, benzofurans, and cannabinoids | — |
| 9 | Unigene Laboratories Biopharmaceutical company engaged in R&D of peptides | $38M | 159 mo ago | 53 | Ashleigh Palmer ex-CEO | — | 14 patents Peptide therapeutics and delivery systems for obesity, bone regeneration, and recombinant production | — |
| 10 | Drais Pharma Innovating healthcare with impactful pharmaceutical solutions, research, and patient-centered care | $33M | 152 mo ago | 6 | — | — | — | — |
| 11 | Prolong Pharma Products for hematology and oncology indications | $30M | 189 mo ago | 3 | — | WebflowVimeojsDelivr+8 | — | — |
| 12 | Innopharma Biopharma company focused on manufacturing generic as well as specialty products | $15M | 152 mo ago | 23 | — | — | 100 patents Sterile infusion bag packaging for oxidation‑sensitive injectable pharmaceutical formulations | — |
| 13 | Zennova Manufacturer of drugs | $14M | 36 mo ago | — | Dahai Guo Co-Founder & CEO | — | 3 patents Characterizing release and uptake of poorly soluble materials in complex liquid systems | — |
| 14 | Eagle Pharmaceuticals Pharmaceutical company advancing treatments for critical care and oncology patients | $12M | 116 mo ago | 134 134 → 100 (-25%) | — | Master SliderSlider RevolutionWordPress+25 | 332 patents Pharmaceutical formulations and delivery methods for oncology and CNS therapeutic agents | — |
| 15 | Conjupro Biotherapeutics Biopharmaceutical company offering diversified research and development solutions | $9M | 35 mo ago | 18 | Qingxi Wang CEO | — | — | — |
| 16 | Cambridge Therapeutic Technologies Limited information available | $6M | 118 mo ago | 6 | — | — | — | — |
| 17 | Moerae Matrix Indonesian news portal delivering trusted updates on business, finance, and more | $6M | 163 mo ago | 9 | Cynthia Lander CEO & Chairman | — | 120 patents Anti‑fibrotic therapeutics targeting fibroblast proliferation and extracellular‑matrix deposition | — |
| 18 | Abeille Pharmaceuticals Late-stage drug development company focusing on oncology and diabetes, with expertise in oral sustained… | $3M | 208 mo ago | — | Suresh Borsadia CEO & President | — | — | — |
| 19 | CorMedix Commercial stage biopharma company with focus on cardiac, renal and infectious diseases | $3M | 107 mo ago | 40 | — | WordPressMySQLPHP+19 | 130 patents Taurolidine synthesis, antimicrobial hydrogels, and oncology/antifungal drug formulations | — |
| 20 | Origin Developer of drug delivery platform for skin and soft-tissue infections | $2M | 33 mo ago | 7 | — | — | 148 patents Medical nitric oxide generation and delivery devices for therapeutic and diagnostic applications | — |
| 21 | Alitair Pharmaceuticals Developing respiratory therapies, including prescription cough medicines and orphan drugs | $1M | 69 mo ago | 3 | William Howard Founder | — | — | — |
| 22 | Provid Pharmaceuticals Developing MHC inhibition drugs for multiple sclerosis and autoimmune diseases | $400K | 144 mo ago | 5 | Gary Olson President & CEO | — | — | — |
| 23 | Herborium Botanical therapeutics company focused on natural medicinal products for unmet medical needs | $95K | 176 mo ago | 9 | — | — | — | — |
| 24 | Johnson & Johnson Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | — | 17 mo ago | 131,900 131,900 → 132,799 (+1%) | Joaquin Duato CEO | BrightspotJavaFacebook Login+22 | 1,517 patents Advanced medical diagnostics, surgical instrumentation, and wireless communication technologies. | — |
| 25 | Merck Sharp & Dohme Developer of therapies to treat multiple diseases | — | 82 mo ago | 1,500 | Yash Goyal Managing Director | ScalaPlayBootstrap+20 | 19,165 patents Therapeutic small molecules and biologics for oncology, immunotherapy, and viral infections | — |
| 26 | Allergan Developer and manufacturer of portfolio of generic medicines | — | 98 mo ago | 18,000 | Gavin Herbert Founder | — | 12,303 patents Ophthalmic drug delivery systems, botulinum toxin production, and injectable dermal filler technologies. | — |
Top 12 Diversified Pharmaceuticals companies in New Jersey
#1
Public · Cranbury, New Jersey · founded 1996 · 34 employees$77.7Mraised▾
Innovating melanocortin therapeutics for inflammatory, autoimmune, and ocular diseases. The company discovers and develops novel therapeutics, leveraging the melanocortin system to resolve harmful inflammation. Focused on inflammatory and autoimmune diseases, particularly ocular conditions, they aim to provide effective, safe, and tolerable treatments. Their expertise spans drug discovery through FDA approval, with a vision to merge future-focused intention with data-driven innovation. They are committed to developing groundbreaking therapeutics, driving a culture of science and innovation to address unmet medical needs. They are focused on research and development activities, and strategic partnerships.
- May 2022Post IPO—
- Dec 2014Post IPO$20M
- Jul 2012Post IPO$35M
- Jan 2004Post IPO$22.7M
#2
Series B · Princeton, New Jersey · founded 2014$13.9Mraised▾
Manufacturer of drugs
- Jul 2023Series B$13.9M
- Aug 2021Series A—
#3
Series A · Princeton, New Jersey · founded 2017 · 18 employees$9.3Mraised▾
Biopharmaceutical company offering diversified research and development solutions. It provides pre-clinical research and development services, and develops medicines in oncology, central nervous system, and infectious disease areas.
- Sep 2023Series A$9.3M
#4
Acquired · Bridgewater, New Jersey · founded 1989 · 1000 employees$345Mraised▾
Gastrointestinal specialty pharmaceutical company dedicated to advancing treatment and patient care. The company focuses on innovative solutions for a wide range of gastrointestinal diseases and conditions. They are committed to rigorous research and development to advance innovative products. The company works side by side with patients, healthcare professionals, and educational organizations in the ongoing pursuit of life-changing healthcare. They offer effective treatments and are building a community based on integrity and mutual respect. The company is dedicated to constant innovation with endless possibilities in the pharmaceutical industry. They are hiring dedicated and innovative team members who want to make a difference.
- Nov 2013Conventional Debt$750M
- May 2001Post IPO$28M
- 1999Convertible Debt$345M
#5
Acquired · Parsippany Troy Hills, New Jersey · founded 1996 · 60 employees$400Mraised▾
The Medicines Company vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company markets Angiomax(R) (bivalirudin) for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion for the reduction of blood pressure. It has two products in late stage development: cangrelor, an antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company’s pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.
- Jun 2016Post IPO—
- Jan 2015Post IPO$400M
#6
Public · Cranford, New Jersey · founded 2007 · 22 employees$43.3Mraised▾
Developer of drugs for the infectious and gastrointestinal diseases
- Jan 2021Post IPO$20M
- May 2020Post IPO$220.6K
- Apr 2019Post IPO$5.3M
- Aug 2018Post IPO$10M
#7
Seed · Princeton, New Jersey · founded 2010 · 7 employees$1.9Mraised▾
Origin is involved in developing a drug delivery platform for skin and soft-tissue infections such as diabetic foot ulcers. They have developed a patented technology, IonoJet, which enables targeted delivery of nitric oxide (directly to treatment site), produced at the point of therapy from room air in a vehicle. Their products include IonoStim (for wound healing), Ionoderma (for onychomycosis), Ionosite (for arthritis and tendinitis), and Ionodent (for periodontitis and implantitis).
- Oct 2023Seed$51K
- Jun 2023Seed$500K
- May 2017Seed$1.3M
#8
Acquired · Summit, New Jersey · founded 1986 · 4891 employees$45Mraised▾
Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The company's lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of $15.28B, and a net profit of $4.04B.
- Feb 2018Post IPO$4.1M
- Nov 2017Conventional Debt$3B
- Apr 2015PE$45M
- Mar 2013Grant (prize money)$7.5M
#9
Deadpooled · Iselin, New Jersey · founded 1990$41.1Mraised▾
Pharmos is a US-based, clinical-stage biopharma developing therapeutics for Neurology, Gastrointestinal, Endocrine/Metabolic disorders. They work on disorders like gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. The Company's product Dextofisopam is used for the treatment of irritable bowel syndrome (IBS). It was developing levotofisopam for Hyperuricemia/gout. The company appears deadpooled currently.
- Apr 2009Post IPO$1.8M
- Jan 2008Post IPO$4M
- Mar 2007Grant (prize money)—
- May 2005Grant (prize money)$1.3M
#10
Series C · Boonton, New Jersey · founded 1983 · 53 employees$37.8Mraised▾
Unigene was a publicly traded biopharmaceutical company engaged in R&D of peptides for medical purposes. The firm was best known for a way to turn injectable peptide drugs into pills. The firm had also licensed an oral calcitonin tablet to Tarsa Therapeutics in 2009, grabbing a 16% equity stake as part of the deal, along with a royalty stream. Unigene eventually defaulted on the debt payments and was liquidated through public auctions under Article 9 of Uniform Commercial Code.3 of the firm's old leadership - Brian Zietsman, Nozer Mehta, and Paul Shields - have got together to form a newer company on similar lines, called Enteris pharmaceuticals.
- Apr 2013Series C$750K
- Sep 2012Series C$4M
- Mar 2010Series C$33M
#11
Acquired · Bedminster, New Jersey · founded 1986 · 365 employees$50Mraised▾
Global pharmaceutical company committed to better health and a brighter future. It focuses on moving science forward to transform lives through innovative medicines. The company operates in areas like gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. It is dedicated to research and development, manufacturing, and ensuring access to medicines globally. The company emphasizes corporate responsibility, sustainability, and ethical practices. It engages with investors, healthcare professionals, and patients, aiming to deliver on its commitment to people and the planet. The company is involved in clinical trials and collaborative studies to advance medical knowledge and treatment options.
- Aug 2014PE$50M
#12
Acquired · Iselin, New Jersey · founded 2008$49Mraised▾
Small molecule drugs for metabolic and oncologic disorders. Its pipeline of products includes anamorelin which was in phase 2 trials for the treatment of cancer cachexia; ipamorelin in phase 2 trials for the treatment of postoperative ileus and ST-114 in phase 1 trials for the treatment of opioid-induced bowel dysfunction.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.